The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

The startup will also use its generative AI technology to optimize manufacturing of the gene therapy, leveraging data that MeiraGTx has amassed over the course of nearly a decade developing its ...

Spatial transcriptomics is an advanced technique that analyzes gene expression within tissue sections, such as those from the ...

Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.

Gene therapy specialist MeiraGTx is spinning some of its experimental medicines for the central nervous system into a startup that hopes to develop them further using artificial intelligence. Aptly ...

This iterative, human-in-the-loop process allowed for refinement of the AI-generated assessments. This process, although more labor-intensive, provides a level of scrutiny and validation essential for ...

a gene therapy for Parkinson’s disease. The agreement, which will also expand the firm’s manufacturing operations, is valued at up to $430 million. It includes the creation of a joint venture, Hologen ...

Also: cheap Excel and Office training available, an AI startup challenges Intuit and Xero and reasons why Manus is over-hyped ...

artificial intelligence (AI) has been quietly improving the sector for years, from candidate prioritization in drug discovery to adverse event triage in clinical trials. Still, there are plenty of ...

That's not exactly the narrative Silicon Valley wants you to hear.  But pay no attention to what those companies are saying.